Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, meningococcal group C tetanus toxoid conjugate vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK Biologicals' DTPa-IPV/Hib-MenC-TT is an investigational hexavalent combination vaccine designed to protect infants against six major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, Haemophilus influenzae type b (Hib), and meningococcal serogroup C (MenC). The vaccine combines diphtheria and tetanus toxoids, acellular pertussis antigens (including pertussis toxoid, filamentous hemagglutinin, and pertactin), inactivated poliovirus strains (types 1, 2, and 3), and capsular polysaccharides from Hib and MenC, both of which are conjugated to a tetanus toxoid carrier protein. Developed to simplify infant immunization schedules by reducing the number of injections, this vaccine was evaluated in Phase II clinical trials (such as NCT00871338) where it demonstrated non-inferiority to the separate administration of DTPa-IPV/Hib and MenC vaccines. It is currently considered a research/investigational compound and has not received a distinct approved brand name as a standalone product.
- Other names
- GSK hexavalent DTPa-IPV/Hib-MenC-TT vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRP (Haemophilus influenzae type b capsular polyribosylribitol phosphate)Poliovirus type 3 virion epitopesNeisseria meningitidis group C capsular polysaccharidePRN (Pertactin)Diphtheria toxinPoliovirus type 2 virion epitopesPoliovirus type 1 virion epitopesBCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, meningococcal group C tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, meningococcal group C tetanus toxoid conjugate vaccine.